Moderna, Inc. (MRNA) · Insider Trading (Form 4) SEC Filing

=== SEC Form 4 — Statement of Changes in Beneficial Ownership === Document Type: 4 Period of Report: 2026-07-05 10b5-1 Pre-arranged Plan: No --- Issuer --- Name: Moderna, Inc. (MRNA) CIK: 0001682852 --- Reporting Owner --- Name: Banque Soria Ester CIK: 0001985166 Role: Officer (Chief Commercial Officer) --- Derivative Transactions --- [Transaction #1] Security: Stock Option (Right to Buy) Date: 2026-07-05 | Code: A (Grant or award) Shares: +18,658 | Price: $0.00 Exercisable: N/A | Expires: 2036-07-05 Shares Owned After: 18,658 | Ownership: D (Direct) Footnotes: [F1] 25% of this option will vest and become exercisable on July 5, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter. [Transaction #2] Security: Restricted Stock Units Date: 2026-07-05 | Code: A (Grant or award) Shares: +38,364 | Price: $0.00 Shares Owned After: 38,364 | Ownership: D (Direct) Footnotes: [F2] Restricted stock units convert into common stock on a one-for-one basis. [F3] 25% of the shares subject to this restricted stock unit award will vest on July 5, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter. [F3] 25% of the shares subject to this restricted stock unit award will vest on July 5, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter. --- Footnotes (Complete Index) --- F1: 25% of this option will vest and become exercisable on July 5, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F2: Restricted stock units convert into common stock on a one-for-one basis. F3: 25% of the shares subject to this restricted stock unit award will vest on July 5, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter. --- Signature --- /s/ /s/ James Dillon, as Attorney-in-Fact (2026-07-07)